In patients without lymph node metastasis and with disease free survival time greater than or equal to 12 months (n=120), high MCL1 gain was associated with better DFS (P=0.009) and OS (P=0.014) (Figure 2). Here, MCL1 is linked to metastatic malignant neoplasm in the lymph nodes.